Construction of a bivalent vaccine candidate against HAdV4/HAdV7 based on capsid-display strategy via Red-homologous recombination and counter-selection methodology

作     者：Peng Wang Yunting Shao Xichun Yang Wenning Zhang Jianguang Zhou Fang Huang Shuang Liu Jiping Zheng Chengjun Wu Shanhu Li 

作者机构：Department of Cell EngineeringBeijing Institute of BiotechnologyBeijing 100850China School of Basic Medical SciencesFaculty of MedicineDalian University of TechnologyDalian 116024China Lab of Microbiological EngineeringSchool of Life and Health SciencesHainan UniversityHaikou 570228China 

出 版 物：《Biosafety and Health》 (生物安全与健康（英文）)

年 卷 期：2024年第6卷第2期

页      面：70-79页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：supported by grants from the National Key Research and Development Program of China(Grant No.2018YFA0900800) 

主　　题：Bivalent adenovirus vaccine Capsid-display strategy ITRs modification Hexon epitope replacement 

摘      要：Human adenoviruses(HAdvs)are major respiratory ***,human adenovirus type 4(HAdV4)and human adenovirus type 7(HAdV7)are known for causing fever and pneumonia,with docu-mented cases of fatalities among the *** recent years,HAdV4/HAdv7 has been implicated in caus-ing substantial outbreaks,leading to increased morbidity in multiple *** HAdV4 and HAdV7 infections have been reported in North America,Asia,Europe,Africa,South America,Oceania,and the Middle *** fatalities occurred in North America(the United States)and Asia(China and Singapore).Engineered recombinant adenoviruses have played a crucial role as vaccine *** this study,we con-structed a recombinant adenovirus,Ad4ITRmut-Ad7E3,and evaluated it in vitro and in *** observed that the replication rate of Ad4ITRmut-Ad7E3 was lower than that of the RI-67 strain,indicating that the mutation of inverted terminal repeats(ITRs)weakened the replication ability of *** of BALB/c mice with the bivalent Ad4ITRmut-Ad7E3 vaccine strain,administered by intraperitoneal injection and oral gavage,resulted in the elicitation of neutralizing antibodies targeting HAdV4 and *** finding not only pro-vides a novel method and technique for the efficient construction of a polyvalent recombinant adenovirus vac-cine candidate against HAdV4 and HAdv7 but also against other prevalent adenovirus serotypes such as HAdV3,HAdV11,HAdV14,and HAdv55,from various regions.